OncoSil Medical Ltd (AU:OSL) has released an update.
OncoSil Medical has announced the successful expansion of its OncoSilTM device treatments for pancreatic cancer into Austria, marking the product’s presence in four European countries. The first two patients in Austria were treated at the Universitätsklinikum St. Pölten, signaling OncoSil’s continued penetration into key European markets, with future expansions anticipated in the UK, Portugal, and Germany.
For further insights into AU:OSL stock, check out TipRanks’ Stock Analysis page.
